December 2016
-
AIM ImmunoTech has announced a planned Phase 2a human challenge trial of intranasal Ampligen rintatolimod against human rhinovirus and influenza. The company suggested that “Success against these common viruses could also indicate that an Ampligen… Read more . . .
-
Opiant Pharmaceuticals said that a PK study of its OPNT003 intranasal nalmefene, which it is developing for opioid overdose, demonstrated that the Tmax of the nasal formulation was about 15 minutes, similar to that shown… Read more . . .
-
Anindya Roy, a researcher at the University of Washington Institute for Protein Design (IPD), has received a $250,000 grant from Washington Research Foundation (WRF) for continued development of an inhaled miniprotein binder for the treatment of… Read more . . .
-
Rokote Laboratories, a spin out from the University of Helsinki and the University of Eastern Finland, has raised €9 million for development of an intranasal vaccine against the SARS-CoV-2 virus, the universities have announced. The… Read more . . .
-
Atossa Therapeutics said that the Human Research Ethics Committee (HREC) of the Australian National Health and Medical Research Council (NHMRC) has okayed a Phase 1/2a clinical study of the company’s nebulized AT-H201, which is “is… Read more . . .
-
Dutch DPI developer Pure IMS has announced a new partnership with CDMO Sever Pharma Solutions (formerly Disphar International) and Radboud University Medical Center (Radboudumc) for development of a tigecycline dry powder inhaler for the treatment… Read more . . .
-
Levo Therapeutics announced that the FDA has accepted the company’s NDA for LV-101 intranasal carbetocin for the treatment of excessive hunger associated with Prader-Willi syndrome (PWS) and has granted the NDA Priority Review designation, with… Read more . . .
-
M8 Pharmaceuticals said that it has acquired exclusive rights to market Marinomed’s Carragelose nasal spray in Brazil and Mexico. The company will market the product in those countries as Barlo nasal spray for the prevention… Read more . . .
-
The Australian Therapeutic Goods Administration has issued 7 infringement notices to Starpharma regarding advertising of the company’s Viraleze astodrimer sodium antiviral nasal spray, with fines totaling $93,240. The news comes shortly after after the UK… Read more . . .
-
Inhalation Sciences (ISAB) announced that its CRO division, Inhalation Research Services (IRS), has signed an agreement with “an innovative US pharma company that is developing novel mRNA therapies for the treatment of cystic fibrosis and other… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland